FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

Akeso initiates a pivotal trial for cadonilimab and lenvatinib, targeting advanced liver cancer resistant to PD-1 therapy, ...

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...